包涵体肌炎吞咽困难的诊断与管理:一项系统综述
该系统综述检索多引擎数据库,最终纳入19项针对包涵体肌炎(IBM)患者吞咽困难的干预研究,多数研究质量评为差。环咽肌功能障碍是最常报告的吞咽异常(12/19),免疫抑制剂、肉毒毒素注射、球囊扩张和/或环咽肌切开术带来混合且短暂的获益,而他汀类或行为疗法未见对吞咽困难有效。
要点
- 环咽肌功能障碍是IBM吞咽困难中最常报告的吞咽异常(12/19项研究)。
- 免疫抑制剂、肉毒毒素注射、球囊扩张和/或环咽肌切开术的获益为混合且短暂。
- 纳入研究多为低质量证据,作者提醒不宜将结果普遍化并需进一步系统研究。
核心结论
- 多种干预被报告可暂时改善IBM患者的吞咽困难,但这些发现基于有限且总体低质量的证据。
- 作者提醒不宜将这些发现普遍化,并强调需要进一步系统研究以改善IBM吞咽困难的诊断与管理。
研究设计与样本
- 遵循PRISMA 2020指南进行多引擎检索的系统综述,纳入标准为对IBM患者实施干预、报告吞咽结局并以英文发表的研究。
- 共检索到239项研究,19项符合纳入标准,并对纳入研究进行质量评价。
主要发现
- 19项研究中1项质量评为「尚可」,其余评为「差」,主要因缺乏已发表且经过验证的吞咽评估程序和结局指标。
- 环咽肌功能障碍是最常报告的吞咽异常(12/19)。
- 干预类型包括药物治疗(10/19)、手术治疗(3/19)、行为治疗(1/19)和联合方法(5/19)。
- 免疫抑制剂、肉毒毒素注射、球囊扩张和/或环咽肌切开术带来混合且短暂的获益。
- 少数考察他汀类或行为疗法(主要关注呼吸功能)的研究显示对吞咽困难无效果。
局限性
- 19项研究中1项质量评为「尚可」,其余评为「差」,主要因缺乏已发表且经过验证的吞咽评估程序和结局指标。
- 作者结论指出这些发现基于有限且总体低质量的证据。
- 作者提醒不宜将这些发现普遍化,并强调需要进一步系统研究以改善IBM吞咽困难的诊断与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Dysphagia is a common debilitating clinical feature of IBM. However, the impact of dysphagia in IBM has been historically overlooked. This study aimed to identify, evaluate and summarize the evidence regarding the assessment and management of dysphagia in persons with IBM undergoing treatment. METHODS: A systematic review was conducted using a multiengine search following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Eligible studies had to employ an intervention for persons with IBM, report a swallowing outcome and be published in English. Quality assessments of the eligible studies were performed. RESULTS: Of 239 studies found, 19 met the inclusion criteria. One study was rated as 'fair' and the rest as 'poor' quality, particularly due to the lack of published and validated swallowing assessment procedures and outcome measures. Cricopharyngeal (CP) dysfunction (12/19) was the most commonly reported swallowing abnormality. Interventions for disease management included pharmacological agents (10/19), followed by surgical (3/19), behavioral (1/19) and combined approaches (5/19). Interventions with immunosuppressants, botulinum toxin injection, balloon dilation and/or CP myotomy led to mixed and transient benefits. Few studies examining statins or behavioral therapies (primarily focused on respiratory function) showed no effects for dysphagia. CONCLUSION: Various interventions have been reported to temporarily improve dysphagia in persons with IBM. However, these findings are based on limited and overall low-quality evidence. This study cautions against the generalization of these findings and emphasizes the need for further systematic research to improve the diagnosis and management of dysphagia in IBM.
引用
- Ambrocio KR, Garand KLF, Roy B, et al. Diagnosing and managing dysphagia in inclusion body myositis: a systematic review. Rheumatology (Oxford). 2023. PMID: 37115631. doi:10.1093/rheumatology/kead194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。